New immunotherapy agent toripalimab demonstrated positive outcome regarding progression-free survival, rate and duration of response when associated with conventional chemotherapy in nasopharyngeal carcinoma treatment.
In this context, the findings of phase III JUPITER-02 research with toripalimab were presented, during the ASCO 2021 higher importance plenum. “It’s the first study to highlight unequivocal benefit of an immunotherapy agent on metastatic nasopharyngeal carcinoma first line treatment”, says oncologist João Paulo Vasconcelos, from Belo Horizonte Oncocentro, part of the Oncoclinicas Group.
According to Cristiano Guedes, oncologist from Rio de Janeiro Oncoclinicas, it’s vital to highlight that a patient with recurring or oligometastatic illness should be, first and foremost, evaluated by a multidisciplinary team. “Once the possibility of locoregional therapy, such as surgery or re-radiation, is discarded, systemic treatment is advised. Preferential treatment consists of using cisplatin and gemcitabine. Other composite options might be considered, such as carboplatin and gemcitabine, platinum (carboplatin or cisplatin) partnered with paclitaxel or docetaxel. Single agents, such as platinum, taxanes, methotrexate or capecitabine, may also be used.”
To read the full article with all research details, access our website.